Paper Details

  1. Home
  2. Paper Details

Transplantation strategies in AML: AMLCG data.

Author: , BerdelW E, BerningB, BüchnerT, HeineckeA, HiddemannW, KienastJ, KrögerM, SauerlandM C, SchochC, StelljesM, WörmannB

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Allogeneic stem cell transplantation (allo-SCT) is the most effective treatment after remission for acute myeloid leukemia (AML), but it can be dangerous. The benefits of reducing relapse are not always reflected in improved overall survival due to risks associated with the procedure. Allo-SCT is generally recommended only for younger, healthy patients who have a high risk of relapse and a suitable sibling donor. For patients with high-risk features, a transplant using a different donor is an option and should be part of a clinical trial.
Paper Details　
Original Abstract of the Article :
Allogeneic stem cell transplantation (allo-SCT) is considered the most potent postremission therapy for acute myeloid leukemia (AML). Its superior antileukemic activity is largely ascribed to the powerful graft-versus-leukemia (GvL) effects exerted by donor lymphocytes. However, due to considerable ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s00277-004-0850-2

データ提供：米国国立医学図書館（NLM）

Navigating the Shifting Sands of AML Treatment

Acute myeloid leukemia (AML) is a formidable foe, a sandstorm sweeping across the body, threatening the delicate balance of health. This study explores the shifting sands of AML treatment, focusing on the powerful weapon of allogeneic stem cell transplantation (allo-SCT).

The researchers examine the role of allo-SCT in AML, recognizing its potent antileukemic activity, particularly its graft-versus-leukemia (GvL) effects. However, the study acknowledges the significant treatment-related lethality associated with allo-SCT, a reminder that even powerful weapons can come with a price. It's like navigating a desert landscape, understanding the trade-offs between potential benefits and risks.

The Search for Optimal Treatment Strategies

The study highlights the importance of carefully selecting appropriate patients for allo-SCT, emphasizing the need for individualized treatment plans. It's like choosing the right path through a desert, considering the specific challenges and resources available.

Finding the Right Oasis in AML Treatment

This study provides valuable insights into the complexities of AML treatment, emphasizing the need for careful consideration of all treatment options and their potential impact on the patient's health. It's a reminder that the desert of AML can be vast and unforgiving, but with careful navigation and informed decisions, we can find oases of hope and healing.

Dr. Camel's Conclusion

This study provides a comprehensive analysis of allo-SCT in AML, highlighting the need for careful patient selection and personalized treatment strategies. It's a reminder that the battle against AML is a long and arduous journey, but with continued research and understanding, we can find new pathways to victory.

Date :
  1. Date Completed 2004-06-30
  2. Date Revised 2004-11-17
Further Info :

Pubmed ID

15124707

DOI: Digital Object Identifier

10.1007/s00277-004-0850-2

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.